Tags

Type your tag names separated by a space and hit enter

The evaluation of rifampicin bioavailabilities of fixed-dose combinations of anti-tuberculosis drugs: procedures for ensuring laboratory proficiency.
Int J Tuberc Lung Dis. 1999 Nov; 3(11 Suppl 3):S322-4; discussion S351-2.IJ

Abstract

SETTING

The perceived need to demonstrate whether or not the rifampicin bioavailability of commercially manufactured fixed-dose combinations is satisfactory.

OBJECTIVE

To establish an international laboratory network to assess rifampicin bioavailability.

DESIGN

Convenient assay kits were devised to evaluate the ability of laboratories in China, India, Italy, South Africa, Thailand and the USA to determine plasma and urinary concentrations of rifampicin and desacetyl-rifampicin.

RESULTS

Five laboratories, all of whom used high pressure liquid chromatographic methods, were shown to be able to accurately and precisely determine the two compounds.

CONCLUSION

Such a procedure is simple, convenient and objective and could be further employed to enlarge the intended international laboratory network.

Authors+Show Affiliations

Department of Medical Microbiology, St. George's Hospital Medical School, London, UK.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

10593711

Citation

Ellard, G A.. "The Evaluation of Rifampicin Bioavailabilities of Fixed-dose Combinations of Anti-tuberculosis Drugs: Procedures for Ensuring Laboratory Proficiency." The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease, vol. 3, no. 11 Suppl 3, 1999, pp. S322-4; discussion S351-2.
Ellard GA. The evaluation of rifampicin bioavailabilities of fixed-dose combinations of anti-tuberculosis drugs: procedures for ensuring laboratory proficiency. Int J Tuberc Lung Dis. 1999;3(11 Suppl 3):S322-4; discussion S351-2.
Ellard, G. A. (1999). The evaluation of rifampicin bioavailabilities of fixed-dose combinations of anti-tuberculosis drugs: procedures for ensuring laboratory proficiency. The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease, 3(11 Suppl 3), S322-4; discussion S351-2.
Ellard GA. The Evaluation of Rifampicin Bioavailabilities of Fixed-dose Combinations of Anti-tuberculosis Drugs: Procedures for Ensuring Laboratory Proficiency. Int J Tuberc Lung Dis. 1999;3(11 Suppl 3):S322-4; discussion S351-2. PubMed PMID: 10593711.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The evaluation of rifampicin bioavailabilities of fixed-dose combinations of anti-tuberculosis drugs: procedures for ensuring laboratory proficiency. A1 - Ellard,G A, PY - 1999/12/11/pubmed PY - 1999/12/11/medline PY - 1999/12/11/entrez SP - S322-4; discussion S351-2 JF - The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease JO - Int J Tuberc Lung Dis VL - 3 IS - 11 Suppl 3 N2 - SETTING: The perceived need to demonstrate whether or not the rifampicin bioavailability of commercially manufactured fixed-dose combinations is satisfactory. OBJECTIVE: To establish an international laboratory network to assess rifampicin bioavailability. DESIGN: Convenient assay kits were devised to evaluate the ability of laboratories in China, India, Italy, South Africa, Thailand and the USA to determine plasma and urinary concentrations of rifampicin and desacetyl-rifampicin. RESULTS: Five laboratories, all of whom used high pressure liquid chromatographic methods, were shown to be able to accurately and precisely determine the two compounds. CONCLUSION: Such a procedure is simple, convenient and objective and could be further employed to enlarge the intended international laboratory network. SN - 1027-3719 UR - https://www.unboundmedicine.com/medline/citation/10593711/The_evaluation_of_rifampicin_bioavailabilities_of_fixed_dose_combinations_of_anti_tuberculosis_drugs:_procedures_for_ensuring_laboratory_proficiency_ L2 - http://www.diseaseinfosearch.org/result/7252 DB - PRIME DP - Unbound Medicine ER -